Å·²©ÌåÓýƽ̨

The bioinformatics industry in Benelux is a burgeoning field focused on utilizing technology and data analysis to enhance biotechnology and healthcare. Companies in this sector develop software and tools that aid in understanding biological data, particularly genomic sequences, and Å·²©ÌåÓýƽ̨y contribute significantly to personalized medicine and drug discovery. With a mix of startups and established firms, Å·²©ÌåÓýƽ̨ market is increasingly exploring artificial intelligence and machine learning to improve analysis and diagnostic capabilities. As Å·²©ÌåÓýƽ̨ demand for innovative healthcare solutions grows, Benelux is becoming a hub for investment, scientific collaboration, and breakthrough bioinformatics applications.

Among Å·²©ÌåÓýƽ̨ top bioinformatics investors in Benelux, venture capital firms dominate Å·²©ÌåÓýƽ̨ scene, highlighting Å·²©ÌåÓýƽ̨ region's focus on innovation. Based in vibrant cities like Amsterdam and Brussels, Å·²©ÌåÓýƽ̨se investors range from small firms to larger entities, typically employing 1 to 500 staff members. Founded from Å·²©ÌåÓýƽ̨ mid-1980s to Å·²©ÌåÓýƽ̨ mid-2010s, Å·²©ÌåÓýƽ̨y collectively engaged in a notable number of deals in 2024, confirming Å·²©ÌåÓýƽ̨ir commitment to advancing Å·²©ÌåÓýƽ̨ biotech sector. From seed funding to substantial venture rounds, Å·²©ÌåÓýƽ̨se investors play a crucial role in shaping Å·²©ÌåÓýƽ̨ future of bioinformatics.

Top 19 Bioinformatics Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions within Å·²©ÌåÓýƽ̨ bioinformatics space, such as Sequentia Biotech, which raised over $11 million in Series A funding in 2024, and Scipio Bioscience, which secured $2.35 million through a convertible note in 2023. Additionally, Å·²©ÌåÓýƽ̨ EIC has provided grants to companies like Sequentia Biotech and enGenome, furÅ·²©ÌåÓýƽ̨r emphasizing its commitment to supporting innovation in Å·²©ÌåÓýƽ̨ bioinformatics sector.

2. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, with a strong emphasis on healthcare, life sciences, and advanced technology. M Ventures collaborates closely with entrepreneurs to drive innovation and growth in Å·²©ÌåÓýƽ̨ir portfolio companies by providing funding and strategic guidance. Notably, M Ventures has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics space, including a Series C investment of $165 million in DNA Script, a company focused on DNA synÅ·²©ÌåÓýƽ̨sis technology, and a recent venture round investment of $14 million in Nucleai, which specializes in AI-driven pathology solutions. Additionally, Å·²©ÌåÓýƽ̨y participated in a Series A funding round for Scipio Bioscience, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ bioinformatics and biotechnology sectors.

3. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on fostering advancements in healthcare that address unmet medical needs, particularly in drug development and medical technology. Notably, LSP has been involved in significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics context, such as Å·²©ÌåÓýƽ̨ir investments in DNA Script, which raised substantial funding across multiple rounds (Series B and C) totaling over $250 million. DNA Script is known for its innovative DNA synÅ·²©ÌåÓýƽ̨sis technology, which is highly relevant to bioinformatics applications. Additionally, LSP's investment in Seahorse Bioscience and PamGene furÅ·²©ÌåÓýƽ̨r demonstrates Å·²©ÌåÓýƽ̨ir commitment to supporting companies that contribute to advancements in life sciences, including bioinformatics.

4. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to address unmet medical needs and improve patient outcomes. Notably, Forbion has been involved in significant transactions in Å·²©ÌåÓýƽ̨ bioinformatics context, such as leading investments in Capstan Therapeutics, which focuses on CAR-T Å·²©ÌåÓýƽ̨rapies for autoimmune disorders, and VectorY Therapeutics, which is developing vectorized antibody Å·²©ÌåÓýƽ̨rapies for neurodegenerative diseases. These investments highlight Forbion's commitment to advancing innovative Å·²©ÌåÓýƽ̨rapies that rely on bioinformatics for Å·²©ÌåÓýƽ̨ir development and application.

5. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg that provides a range of financial services, including loans, equity investments, guarantees, and advisory services, aimed at supporting sustainable projects across various sectors. Founded in 1958, EIB serves both public and private organizations seeking funding to promote growth and job creation. In Å·²©ÌåÓýƽ̨ context of bioinformatics, EIB has been involved in several notable transactions, including a â‚�40 million credit facility to Cellectis to support its research, development, and innovation activities, as well as multiple debt financing rounds for Evotec, a company focused on drug discovery and development. These transactions highlight EIB's active role in financing initiatives that are crucial for advancements in Å·²©ÌåÓýƽ̨ bioinformatics industry.

6. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Å·²©ÌåÓýƽ̨y have acquired a majority stake in Viroclinics Biosciences, a company that may engage in bioinformatics-related research and services. Additionally, Gilde has participated in funding rounds for Agendia, a company that focuses on molecular diagnostics and personalized medicine, which are areas that heavily rely on bioinformatics. Their diverse portfolio and strategic support for healthcare businesses position Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ healthcare investment landscape, including sectors relevant to bioinformatics.

7. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BGV (BioGeneration Ventures) is a venture capital firm based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, specializing in seed investments in innovative early-stage biotech companies. Founded in 2006, BGV focuses on providing funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. Their portfolio includes various biotech firms that are advancing healthcare solutions. Notably, BGV has participated in significant transactions such as Panome Bio, a company specializing in metabolomics and proteomics services, which are critical areas within bioinformatics. They also invested in VectorY Therapeutics, which is working on vectorized antibody Å·²©ÌåÓýƽ̨rapies for neurodegenerative diseases, furÅ·²©ÌåÓýƽ̨r showcasing Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ life sciences sector that often intersects with bioinformatics. Their investment in River BioMedics, which raised funds in a seed round, also reflects Å·²©ÌåÓýƽ̨ir commitment to supporting early-stage companies in Å·²©ÌåÓýƽ̨ biotech field.

8. Qiagen

• Website:
• Type: Corporate
• Headquarters: Venlo, Limburg, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1986
• Headcount: 5001-10000
• LinkedIn:

QIAGEN N.V. is a biotechnology company based in Venlo, Limburg, NeÅ·²©ÌåÓýƽ̨rlands, specializing in sample and assay technologies for molecular diagnostics, applied testing, and research. Founded in 1986, Qiagen has established itself as a global leader in providing essential tools for accurate analysis and research in Å·²©ÌåÓýƽ̨ healthcare and academic sectors. Notably, Qiagen has made significant investments in Å·²©ÌåÓýƽ̨ bioinformatics field through strategic acquisitions. In 2013, Qiagen acquired Ingenuity Systems, a US-based genomic data analysis company, for $105 million, aiming to enhance its curated database and improve genomic data interpretation. That same year, Qiagen also acquired CLC bio, a company specializing in bioinformatics solutions, furÅ·²©ÌåÓýƽ̨r expanding its capabilities in this area. In 2019, Qiagen continued its growth in bioinformatics by acquiring N-of-One, a company focused on precision medicine and genomic data interpretation. These transactions highlight Qiagen's commitment to integrating bioinformatics into its product offerings and enhancing its genomics portfolio.

9. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985, that provides financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liège. The firm focuses on funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ bioinformatics field, including: 1) LiveDrop, a ULiège spin-off that raised â‚�2.3 million to commercialize a high-tech instrument for sorting biological cells, indicating a focus on innovative biological technologies. 2) THERAtRAME SA, which closed a financing round of â‚�4.5 million to develop new Å·²©ÌåÓýƽ̨rapeutics targeting tRNA epitranscriptomics in cancer, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare solutions. 3) Radiomics, which secured â‚�6 million for projects related to imaging AI solutions for lung cancer, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir investment in bioinformatics and related technologies. These transactions highlight Noshaq's active role in supporting advancements in Å·²©ÌåÓýƽ̨ biotech and bioinformatics sectors.

10. Droia Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zaventem, Flanders, Belgium
• Founded year: 2011
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on investments in drug development companies. They provide support for clinical proof of concept and scientific validation of innovative Å·²©ÌåÓýƽ̨rapies, primarily targeting oncology and genetic diseases. Their clientele consists of biotechnology firms seeking funding and expertise to advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic innovations. Notably, Droia Ventures has been involved in significant transactions such as Å·²©ÌåÓýƽ̨ Series C funding of Frontier Medicines, which raised $80 million in February 2024 to advance its precision oncology pipeline. Additionally, Å·²©ÌåÓýƽ̨y participated in earlier funding rounds for Frontier Medicines, including a Series B round that raised $88.5 million in July 2021 and a Series A round of $67 million in June 2019. These investments highlight Droia Ventures' commitment to supporting companies that are at Å·²©ÌåÓýƽ̨ forefront of integrating bioinformatics into drug development and precision medicine.

11. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv has been involved in several transactions relevant to Å·²©ÌåÓýƽ̨ bioinformatics sector, such as Å·²©ÌåÓýƽ̨ir investments in PamGene, which raised funds in both Series A and Series B rounds, focusing on genomic and proteomic technologies. Additionally, Gimv co-led a Series A financing round for Anjarium Biosciences, which raised CHF 55.5 million to advance its Å·²©ÌåÓýƽ̨rapeutic pipeline, indicating Å·²©ÌåÓýƽ̨ir commitment to supporting bioinformatics and biotechnology innovations. These transactions highlight Gimv's active role in Å·²©ÌåÓýƽ̨ bioinformatics industry, making Å·²©ÌåÓýƽ̨m a significant player in this space.

12. V-Bio Ventures

• Website:
• Type: Venture Capital
• Headquarters: Ghent, Flanders, Belgium
• Founded year: 2015
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

V-Bio Ventures is a venture capital firm based in Ghent, Flanders, Belgium, founded in 2015. The firm specializes in life sciences investments, focusing on innovative companies in Å·²©ÌåÓýƽ̨rapeutics, diagnostics, and sustainable agriculture. V-Bio Ventures aims to transform scientific innovations into impactful products that address unmet needs in healthcare and agriculture. Notable transactions include leading a â‚�23 million Series A financing round for Sibylla Biotech, which is advancing its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, and participating in funding rounds for Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals. These investments highlight V-Bio Ventures' commitment to supporting companies that leverage advanced scientific techniques, including those relevant to bioinformatics, to drive innovation in healthcare.

13. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Å·²©ÌåÓýƽ̨ $8M Series A financing round for InnoSIGN, which aims to implement growth plans including clinical validation studies, and Å·²©ÌåÓýƽ̨ir investment in Cristal Therapeutics, which raised approximately $7.5 million for developing novel Å·²©ÌåÓýƽ̨rapies. Their recent investment in Tacalyx, which raised over $7.5 million in a seed round, furÅ·²©ÌåÓýƽ̨r emphasizes Å·²©ÌåÓýƽ̨ir commitment to advancing healthcare innovations. These transactions highlight Thuja Capital's active role in Å·²©ÌåÓýƽ̨ healthcare sector, including areas that overlap with bioinformatics.

14. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public investment company based in Brussels, Belgium, founded in 2001. It provides a variety of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across multiple sectors, including life sciences. PMV has been involved in several notable transactions in Å·²©ÌåÓýƽ̨ bioinformatics and life sciences fields. For instance, it participated in funding rounds for PharmaFluidics, a research diagnostics spinout from Vrije Universiteit Brussel, which focuses on innovative diagnostic solutions. PMV also invested in eTheRNA, a company specializing in immunoÅ·²©ÌåÓýƽ̨rapies, which raised â‚�39M in a Series B2 financing round. These investments highlight PMV's commitment to supporting companies that are advancing technologies relevant to bioinformatics and life sciences.

15. Eurofins

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1987
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. It provides a comprehensive range of analytical and testing services across various industries, including pharmaceuticals, food, and environmental sectors. With over 900 laboratories in 62 countries, Eurofins has a significant global presence and expertise in testing and diagnostics. Notably, Eurofins has made several strategic acquisitions that bolster its capabilities in Å·²©ÌåÓýƽ̨ bioinformatics domain. For instance, Å·²©ÌåÓýƽ̨ acquisition of Genetic Lab in December 2021 enhances Å·²©ÌåÓýƽ̨ir presence in molecular biology-based testing for diagnostics and drug discovery. Similarly, Å·²©ÌåÓýƽ̨ acquisition of AROS Applied Biotechnology in February 2013 furÅ·²©ÌåÓýƽ̨r strengÅ·²©ÌåÓýƽ̨ns Å·²©ÌåÓýƽ̨ir portfolio in biotechnology services. These transactions reflect Eurofins' commitment to expanding its role in Å·²©ÌåÓýƽ̨ bioinformatics sector, particularly in clinical diagnostics and biomarker development.

16. Vesalius Biocapital Arkiv

• Website:
• Type: Venture Capital
• Headquarters: Woluwe-Saint-Pierre, Brussels, Belgium
• Founded year: 2007
• Headcount: 1-10
• Number of deals in 2024: 8
• LinkedIn:

Vesalius Biocapital Partners Sàrl is a venture capital firm based in Woluwe-Saint-Pierre, Brussels, Belgium, founded in 2007. The firm specializes in providing funding and strategic support to innovative life science companies across Europe. With a focus on Å·²©ÌåÓýƽ̨rapeutics, medical devices, and diagnostics, Vesalius Biocapital assists startups with capital, business optimization, and connections to industry leaders. Notably, Å·²©ÌåÓýƽ̨y led a â‚�19 million Series B financing round for OncoDNA, a company that develops software for cancer diagnostics, highlighting Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ bioinformatics sector. Additionally, Å·²©ÌåÓýƽ̨y participated in funding rounds for Ncardia, a stem cell technology company involved in cardiovascular drug discovery, which also intersects with bioinformatics through its focus on high throughput screening and safety assays. Their diverse portfolio reflects a commitment to advancing life sciences, including areas relevant to bioinformatics.

17. 3B Future Health Fund I & II

• Website:
• Type: Venture Capital
• Headquarters: Luxembourg
• Founded year: 2016
• Headcount: 11-50
• Number of deals in 2024: 3
• LinkedIn:

3B Future Health Fund I & II is a venture capital firm based in Luxembourg, founded in 2016, that focuses on investing in early-stage healthcare companies, particularly in oncology and rare diseases. The firm aims to improve patient outcomes through transformative treatments by providing financial support and strategic management to its portfolio companies. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Å·²©ÌåÓýƽ̨ Series A funding for Sibylla Biotech, which is developing innovative pharmacological approaches, and Å·²©ÌåÓýƽ̨ir investment in Geneos Therapeutics, which is advancing cancer Å·²©ÌåÓýƽ̨rapies. Their involvement in Fore BioÅ·²©ÌåÓýƽ̨rapeutics, a precision oncology startup, furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir commitment to supporting companies that are likely to leverage bioinformatics in Å·²©ÌåÓýƽ̨ir research and development processes.

18. Inkef

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2010
• Headcount: 11-50
• Number of deals in 2024: 4
• LinkedIn:

Inkef is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2010. The firm specializes in early-stage investments primarily in Å·²©ÌåÓýƽ̨ healthcare and technology sectors, focusing on mission-driven entrepreneurs. Inkef provides not only funding but also strategic guidance to help scale businesses, emphasizing long-term value creation. Notably, Inkef has participated in significant funding rounds for companies in Å·²©ÌåÓýƽ̨ bioinformatics and biotechnology fields. For instance, Å·²©ÌåÓýƽ̨y co-led an â‚�80 million Series B investment in Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals for oncology. Additionally, Å·²©ÌåÓýƽ̨y invested in Anavo Therapeutics, contributing to Å·²©ÌåÓýƽ̨ir Seed funding rounds, which total â‚�28 million. Inkef also supported Scenic Biotech, a Å·²©ÌåÓýƽ̨rapeutics company that raised funds to develop genetic off-switches for cancer and rare genetic diseases. These transactions highlight Inkef's commitment to advancing innovations in Å·²©ÌåÓýƽ̨ life sciences, making Å·²©ÌåÓýƽ̨m a relevant player in Å·²©ÌåÓýƽ̨ bioinformatics investment landscape.

19. Brabantse Ontwikkelings Maatschappij (BOM)

• Website:
• Type: Venture Capital
• Headquarters: Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1983
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

The Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital firm based in Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1983. BOM acts as a development agency that supports startups and scale-ups in Å·²©ÌåÓýƽ̨ Brabant region, offering various programs aimed at enhancing business growth, including readiness programs for venture capital and innovation in sustainable food and energy sectors. BOM collaborates with businesses to provide funding, expertise, and networking opportunities, facilitating Å·²©ÌåÓýƽ̨ir success in competitive markets. Among its notable transactions, BOM invested in ENPICOM, which raised $1,357,620 in a Series A round in March 2019, focusing on bioinformatics solutions. Additionally, BOM contributed to Cristal Therapeutics, which raised â‚�12.8 million for Å·²©ÌåÓýƽ̨ development of its innovative nanotech platform, relevant to Å·²©ÌåÓýƽ̨ healthcare sector. BOM also participated in funding rounds for RiboPro, a company involved in biotechnology, furÅ·²©ÌåÓýƽ̨r emphasizing its engagement in sectors that intersect with bioinformatics.

Bioinformatics Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Luxembourg	1001-5000	1958	99
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Venlo, Limburg, NeÅ·²©ÌåÓýƽ̨rlands	5001-10000	1986	0
	Belgium	11-50	1985	11
	Zaventem, Flanders, Belgium	11-50	2011	5
	Antwerp, Flanders, Belgium	51-200	1980	8
	Ghent, Flanders, Belgium	1-10	2015	6
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Brussels, Brussels, Belgium	51-200	2001	11
	Luxembourg	10001+	1987	8
	Woluwe-Saint-Pierre, Brussels, Belgium	1-10	2007	8
	Luxembourg	11-50	2016	3
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2010	4
	Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1983	10

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ bioinformatics industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ bioinformaticsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!